Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8683947 | 0.98 | NUDT1 (0.40) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL23175171 | 0.86 | NUDT1 (0.44) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL2450969 | 0.82 | L3MBTL1 (0.41) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL17697839 | 0.77 | MAPT (0.42) | NUDT1SMN1; SMN2CRHBPCRHR2LMNA | |
| SCHEMBL2784422 | 0.73 | GAA (0.41) | SMN1; SMN2KDM1ATDP1LMNAALDH1A1 | |
| SCHEMBL10639637 | 0.71 | KDM1A (0.38) | SMN1; SMN2KDM1ATDP1LMNAALDH1A1 | |
| SCHEMBL21325614 | 0.69 | ALDH1A1 (0.51) | HRH4SMN1; SMN2TDP1ALDH1A1MAPK1 | |
| SCHEMBL2783128 | 0.68 | GAA (0.52) | SMN1; SMN2L3MBTL1LMNAALDH1A1 | |
| SCHEMBL5033361 | 0.67 | ALDH1A1 (0.54) | HRH4SMN1; SMN2CRHBPCRHR2TDP1 | |
| Hydrochloric Acid SCHEMBL31046080 | 0.67 | ALDH1A1 (0.50) | HRH4SMN1; SMN2KDM4ETDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560817-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | claimed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | NUDT1 4002/4885HRH4 331/4885SMN1; SMN2 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.